Plus Therapeutics Appoints Michael Rosol, Ph.D., as Chief Development Officer
We are excited to announce the appointment of Michael Rosol, Ph.D., as Chief Development Officer at Plus Therapeutics. In this role, Dr. Rosol will oversee the company’s clinical, pre-clinical, and biomarker development efforts, further advancing our mission to develop innovative radiotherapeutics for central nervous system (CNS) cancers.
With 25 years of experience in clinical trial design, operations, and regulatory execution, Dr. Rosol brings a wealth of expertise to Plus Therapeutics. Most recently, he served as Chief Medical Officer and Senior Vice President at Navidea Biopharmaceuticals. Prior to that, he held key leadership positions at Novartis Pharmaceuticals, where he led biomarker development and translational imaging initiatives.
Dr. Rosol earned his Ph.D. from Boston University, specializing in biomedical and radionuclide imaging, and has held academic appointments at:
– Harvard Medical School / Massachusetts General Hospital
– Mayo Clinic
– Children’s Hospital of Los Angeles / USC Medical School
– Medical University of South Carolina
His extensive background in oncology, imaging, and radiopharmaceutical development aligns perfectly with Plus Therapeutics’ commitment to advancing breakthrough treatments for rare and difficult-to-treat cancers, including leptomeningeal metastases (LM) and glioblastoma (GBM).
📢 Read the full Press Release: Click here
#Leadership #OncologyResearch #ClinicalDevelopment #CancerTreatment #NeuroOncology #MedicalInnovation #PSTV
Recent Comments